Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Stimulator of Interferon Genes Pathway Activation as an Immunotherapeutic Strategy for Soft Tissue Sarcoma
EF 2018-19
Résumé
Sarcomas are aggressive cancers derived from bone, muscle, fat, and other connective tissue. Sarcomas are relatively rare; thus, grossly understudied. Conventional treatment consists of radiation, surgery, and chemotherapy, and is rigorous, toxic, and may result in life-long post-operative disabilities from amputations. Furthermore, this treatment is ineffective as roughly 20% of patients develop metastases. Clearly, further research into safer, more effective strategies are needed.
Recently, immune-based therapies have shown promise in regard to several cancers, including lung cancer and melanoma, and several immunotherapy drugs are in clinical trials. Immunotherapy provides a safer alternative treatment to systemic cytotoxic chemotherapy. One immunotherapy in particular caught our interest: stimulator of interferon genes (STING) activation by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) administration. DMXAA is a potent activator of mouse STING. Previous studies found that STING activation is very effective in treating some types of cancers as it upregulates type 1 interferons, which aid in the regulation and development of immune responses. However, STING activation as a therapeutic approach has not been studied in sarcomas.
Herein, we aim to study STING activation as an immunotherapeutic strategy to treat one of the most common adult sarcomas, undifferentiated pleomorphic sarcoma (UPS). Our research plan is to use a mouse model of UPS to test the therapeutic potential of DMXAA. We will monitor the growth or rejection of tumours following DMXAA treatment and uncover the underlying mechanisms of intra-tumoural STING activation. This project is clinically compelling and employs an innovative, safer approach to sarcoma treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406594
Name
Marritt Kayla L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Stimulator of Interferon Genes Pathway Activation as an Immunotherapeutic Strategy for Soft Tissue Sarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
5; 6-Dimethylxanthenone-4-Acetic Acid (Dmxaa); Animal Model; Bone; Immunotherapy; Intra-Tumoural; Metastasis; Sarcoma; Stimulator Of Interferon Genes (Sting); T-Cells; Undifferentiated Pleomorphic Sarcoma (Ups)
Abstract
Sarcomas are aggressive cancers derived from bone, muscle, fat, and other connective tissue. Sarcomas are relatively rare; thus, grossly understudied. Conventional treatment consists of radiation, surgery, and chemotherapy, and is rigorous, toxic, and may result in life-long post-operative disabilities from amputations. Furthermore, this treatment is ineffective as roughly 20% of patients develop metastases. Clearly, further research into safer, more effective strategies are needed.
Recently, immune-based therapies have shown promise in regard to several cancers, including lung cancer and melanoma, and several immunotherapy drugs are in clinical trials. Immunotherapy provides a safer alternative treatment to systemic cytotoxic chemotherapy. One immunotherapy in particular caught our interest: stimulator of interferon genes (STING) activation by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) administration. DMXAA is a potent activator of mouse STING. Previous studies found that STING activation is very effective in treating some types of cancers as it upregulates type 1 interferons, which aid in the regulation and development of immune responses. However, STING activation as a therapeutic approach has not been studied in sarcomas.
Herein, we aim to study STING activation as an immunotherapeutic strategy to treat one of the most common adult sarcomas, undifferentiated pleomorphic sarcoma (UPS). Our research plan is to use a mouse model of UPS to test the therapeutic potential of DMXAA. We will monitor the growth or rejection of tumours following DMXAA treatment and uncover the underlying mechanisms of intra-tumoural STING activation. This project is clinically compelling and employs an innovative, safer approach to sarcoma treatment.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marritt, Kayla L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~